Avoro News

Avoro Capital Updates

We are pleased to share industry insights and updates on Avoro and our portfolio companies. Please reach out if you would like to learn more.

Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform

March 12, 2021 07:00 AM Eastern Standard Time BOSTON–(BUSINESS WIRE)–Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the closing of a $95 million Series C financing. The proceeds will be used to advance its lead development candidate into the clinic, accelerate pipeline growth and …

Read More

Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs

Proceeds to support advancement of the company’s unique discovery platform and robust portfolio of programs focused on high value, traditionally undruggable targets February 24, 2021 08:00 AM Eastern Standard Time SAN DIEGO–(BUSINESS WIRE)–Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers …

Read More

Avoro Ventures Adds Sara Nayeem, MD, as a Partner

February 18, 2021 08:00 AM Eastern Standard Time NEW YORK–(BUSINESS WIRE)–Avoro Ventures announced today that Sara Nayeem, MD, has joined the firm as a Partner, focused on its venture capital investment efforts. Dr. Nayeem joins Avoro Ventures after 12 years with New Enterprise Associates, Inc. (NEA), where she was a Partner in the firm’s biopharma …

Read More

Design Therapeutics Secures $125 Million in Series B Financing to Advance Pipeline of Genomic Medicines for Nucleotide Repeat Expansion Disorders

Arsani William, M.D., of Logos Capital, and John Schmid, Biotech Industry Veteran, Appointed to the Company’s Board of Directors January 27, 2021 08:30 AM Eastern Standard Time SAN DIEGO–(BUSINESS WIRE)–Design Therapeutics, a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide …

Read More

IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology

NEWS PROVIDED BY IO Biotech Jan 13, 2021, 02:00 ET COPENHAGEN, Denmark, Jan. 13, 2021 /PRNewswire/ — IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, announced today that it has raised EUR 127 million in Series B financing. The financing round was led by HBM Healthcare …

Read More